The use of masitinib mesylate has also been evaluated in dogs with melanoma, strongly driven by the fact that c-Kit is a therapeutic target in human melanomas, especially in advanced melanomas with a mutated c-Kit gene 166. The gene discussed is KIT; the disease is melanoma.